Novartis (NVS) agreed to pay more than $345 million to resolve criminal charges brought by federal authorities of using various former and existing subsidiaries to bribe health care providers in different countries to boost prescriptions for its medicines. In doing so, the company becomes the latest in a growing number of drug makers to have violated the Foreign Corrupt Practices Act.

The infractions occurred between 2012 and 2016 in South Korea, Vietnam, and Greece, and involved schemes to increase sales of an eye treatment and contact lenses, among other products. The efforts included payments to “key opinion leaders” who were pressured to write prescriptions and subverting clinical trials in order to more readily promote the medicines that were being studied.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy